Case Reports
doi: 10.1002/1097-0142(197510)36:4<1305::aid-cncr2820360417>3.0.co;2-#.
Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases
- PMID: 1175129
- DOI: 10.1002/1097-0142(197510)36:4<1305::aid-cncr2820360417>3.0.co;2-#
Item in Clipboard
Case Reports
Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases
Cancer.
1975 Oct.
Abstract
A 77-year-old white man with 64 intracutaneous melanoma metastases and a pulmonary metastatic deposit was treated with immunotherapy. Over an 8-month period, 17 intracutaneous lesions were inoculated with BCG. All 17 injected lesions and all 47 uninjected intracutaneous lesions resolved; no new nodules appeared and the pulmonary metastasis regressed (greater than 50%). This is the first documented case of a pulmonary metastatic focus responding to intralesional BCG therapy of intracutaneous metastases.
Similar articles
-
Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.Aust N Z J Surg. 1977 Jun;47(3):362-5. doi: 10.1111/j.1445-2197.1977.tb04303.x. Aust N Z J Surg. 1977. PMID: 269705
-
Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.Cancer. 1975 Feb;35(2):514-20. doi: 10.1002/1097-0142(197502)35:2<514::aid-cncr2820350233>3.0.co;2-f. Cancer. 1975. PMID: 234291
-
The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.Cancer. 1975 Mar;35(3):756-77. doi: 10.1002/1097-0142(197503)35:3<756::aid-cncr2820350331>3.0.co;2-z. Cancer. 1975. PMID: 234295
-
Developments in Intralesional Therapy for Metastatic Melanoma.Cancer Control. 2016 Jan;23(1):12-20. doi: 10.1177/107327481602300104. Cancer Control. 2016. PMID: 27009452 Free PMC article. Review.
-
BCG, levamisole and transfer factor in the treatment of cancer.Prog Exp Tumor Res. 1980;25:178-92. doi: 10.1159/000403181. Prog Exp Tumor Res. 1980. PMID: 6986631 Review. No abstract available.
Cited by
-
Recombinant BCG therapy suppresses melanoma tumor growth.Ann Surg Oncol. 1995 Nov;2(6):542-9. doi: 10.1007/BF02307089. Ann Surg Oncol. 1995. PMID: 8591086
-
Neoadjuvant treatment for melanoma: current challenges and future perspectives.Melanoma Manag. 2016 Jun;3(2):149-159. doi: 10.2217/mmt-2015-0001. Epub 2016 May 25. Melanoma Manag. 2016. PMID: 30190883 Free PMC article. Review.
-
Intralesional therapy for advanced melanoma: promise and limitation.Curr Opin Oncol. 2015 Mar;27(2):151-6. doi: 10.1097/CCO.0000000000000158. Curr Opin Oncol. 2015. PMID: 25629369 Free PMC article. Review.
-
Immunotherapy in the management of melanoma: current status.Immunotargets Ther. 2013 Feb 23;2:1-10. doi: 10.2147/ITT.S30824. eCollection 2013. Immunotargets Ther. 2013. PMID: 27471683 Free PMC article. Review.
-
Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies.Curr Probl Surg. 2022 Jan;59(1):101030. doi: 10.1016/j.cpsurg.2021.101030. Epub 2021 Jul 7. Curr Probl Surg. 2022. PMID: 35033317 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources